View in EDS

Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion.

Saved in:
Bibliographic Details
Title: Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion.
Authors: Shenderov E; Medical Oncology, Johns Hopkins Medicine-The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA., Sharma MR; The START Center for Cancer Research-Midwest, Grand Rapids, Michigan, USA., Garralda E; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Powderly J; Carolina BioOncology Institute, Huntersville, North Carolina, USA., Ługowska I; Centre of Excellence in Precision Cancer Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Spira A; Research Institute, Virginia Cancer Specialists, Fairfax, Virginia, USA., Salamero MC; Medical Oncology Department, Institut Català d'Oncologia, Badalona, Spain., Jang S; Hematology and Oncology, Inova Schar Cancer Institute, Fairfax, Virginia, USA., Cosman R; Medical Oncology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., Shen J; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA., Xu W; Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.; The University of Queensland, St Lucia, Queensland, Australia., Wysocki PJ; Department of Oncology, Jagiellonian University Medical College Hospital, Krakow, Poland., Ramlau R; Medical Oncology, Poznan University of Medical Sciences, Poznan, Poland., Antonarakis ES; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA., Weickhardt AJ; Medical Oncology Department, Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg, Victoria, Australia., Żołnierek J; Department of Clinical Trials, Szamocka Hospital, Lux Med Oncology, Warsaw, Poland., Calvo E; Early Phase Clinical Trials, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain., Zhao E; MacroGenics Inc, Rockville, Maryland, USA., Bohac C; MacroGenics Inc, Rockville, Maryland, USA., Ward A; MacroGenics Inc, Rockville, Maryland, USA., Mallesara G; Medical Oncology, Calvary Mater Hospital Newcastle, Waratah, New South Wales, Australia.
Source: Cancer [Cancer] 2026 Aug 01; Vol. 132 (15), pp. e70544.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42487497
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shenderov+E%22">Shenderov E</searchLink>; Medical Oncology, Johns Hopkins Medicine-The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Sharma+MR%22">Sharma MR</searchLink>; The START Center for Cancer Research-Midwest, Grand Rapids, Michigan, USA.<br /><searchLink fieldCode="AU" term="%22Garralda+E%22">Garralda E</searchLink>; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Powderly+J%22">Powderly J</searchLink>; Carolina BioOncology Institute, Huntersville, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Ługowska+I%22">Ługowska I</searchLink>; Centre of Excellence in Precision Cancer Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Spira+A%22">Spira A</searchLink>; Research Institute, Virginia Cancer Specialists, Fairfax, Virginia, USA.<br /><searchLink fieldCode="AU" term="%22Salamero+MC%22">Salamero MC</searchLink>; Medical Oncology Department, Institut Català d'Oncologia, Badalona, Spain.<br /><searchLink fieldCode="AU" term="%22Jang+S%22">Jang S</searchLink>; Hematology and Oncology, Inova Schar Cancer Institute, Fairfax, Virginia, USA.<br /><searchLink fieldCode="AU" term="%22Cosman+R%22">Cosman R</searchLink>; Medical Oncology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Shen+J%22">Shen J</searchLink>; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Xu+W%22">Xu W</searchLink>; Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.; The University of Queensland, St Lucia, Queensland, Australia.<br /><searchLink fieldCode="AU" term="%22Wysocki+PJ%22">Wysocki PJ</searchLink>; Department of Oncology, Jagiellonian University Medical College Hospital, Krakow, Poland.<br /><searchLink fieldCode="AU" term="%22Ramlau+R%22">Ramlau R</searchLink>; Medical Oncology, Poznan University of Medical Sciences, Poznan, Poland.<br /><searchLink fieldCode="AU" term="%22Antonarakis+ES%22">Antonarakis ES</searchLink>; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Weickhardt+AJ%22">Weickhardt AJ</searchLink>; Medical Oncology Department, Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Żołnierek+J%22">Żołnierek J</searchLink>; Department of Clinical Trials, Szamocka Hospital, Lux Med Oncology, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Calvo+E%22">Calvo E</searchLink>; Early Phase Clinical Trials, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Zhao+E%22">Zhao E</searchLink>; MacroGenics Inc, Rockville, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Bohac+C%22">Bohac C</searchLink>; MacroGenics Inc, Rockville, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Ward+A%22">Ward A</searchLink>; MacroGenics Inc, Rockville, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Mallesara+G%22">Mallesara G</searchLink>; Medical Oncology, Calvary Mater Hospital Newcastle, Waratah, New South Wales, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2026 Aug 01; Vol. 132 (15), pp. e70544.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42487497
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cncr.70544
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e70544
    Titles:
      – TitleFull: Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shenderov E
      – PersonEntity:
          Name:
            NameFull: Sharma MR
      – PersonEntity:
          Name:
            NameFull: Garralda E
      – PersonEntity:
          Name:
            NameFull: Powderly J
      – PersonEntity:
          Name:
            NameFull: Ługowska I
      – PersonEntity:
          Name:
            NameFull: Spira A
      – PersonEntity:
          Name:
            NameFull: Salamero MC
      – PersonEntity:
          Name:
            NameFull: Jang S
      – PersonEntity:
          Name:
            NameFull: Cosman R
      – PersonEntity:
          Name:
            NameFull: Shen J
      – PersonEntity:
          Name:
            NameFull: Xu W
      – PersonEntity:
          Name:
            NameFull: Wysocki PJ
      – PersonEntity:
          Name:
            NameFull: Ramlau R
      – PersonEntity:
          Name:
            NameFull: Antonarakis ES
      – PersonEntity:
          Name:
            NameFull: Weickhardt AJ
      – PersonEntity:
          Name:
            NameFull: Żołnierek J
      – PersonEntity:
          Name:
            NameFull: Calvo E
      – PersonEntity:
          Name:
            NameFull: Zhao E
      – PersonEntity:
          Name:
            NameFull: Bohac C
      – PersonEntity:
          Name:
            NameFull: Ward A
      – PersonEntity:
          Name:
            NameFull: Mallesara G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2026 Aug 01
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0142
          Numbering:
            – Type: volume
              Value: 132
            – Type: issue
              Value: 15
          Titles:
            – TitleFull: Cancer
              Type: main
ResultId 1